WeightWatchers CEO suddenly quits after push to embrace weight-loss drugs like Ozempic, Wegovy
Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.
Weight loss drugs like Ozempic and Wegovy are tremendously popular and effective. Patients should also be careful in using them
Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel full. When the drug interacts with a receptor in the stomach, patients feel full sooner and for a longer period of time after eating. The drug does not cause weight loss directly – instead, it makes you want to eat less.
Ozempic and Wegovy drugmaker CEO defends high costs of drugs
Novo Nordisk chief executive Lars Fruergaard Jørgensen faced questioning on Capitol Hill over the health care costs of the company’s weight-loss drugs Ozempic and Wegovy. NBC News’ Christine Romans reports on how Jørgensen claimed the high prices were due to complications of the U.
Lawmakers challenge drug company CEO over steep prices for Ozempic and Wegovy
Ozempic and Wegovy are some of the most popular drugs in the country, driven by their remarkable success in treating diabetes and obesity. But the drugs are extremely expensive, and the drugmaker’s CEO appeared on Capitol Hill Tuesday to face questions about why those prices are so high.
Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO
Novo Nordisk CEO commits to exploring ways to make weight-loss drugs more affordable for U.S. patients after hearing from Congress.
WeightWatchers CEO Sima Sistani out in abrupt exit, embraced weight loss drugs
WeightWatchers announced Friday that CEO Sima Sistani is no longer at the company, and independent board member Tara Comonte has stepped in to serve as interim CEO.
WeightWatchers' CEO embraced Ozempic. Now she's out of the company.
Sima Sistani helped push the company into the GLP-1 drug space with the $106 million acquisition of Sequence.
WeightWatchers is struggling in the weight loss drug era — and now the CEO is out
International said Friday that CEO Sima Sistani is stepping down immediately. She will be replaced by Tara Comonte, a board member and the former CEO of Shake Shack (SHAK), who was appointed as interim chief executive effective immediately.
Who’s Really Keeping Ozempic and Wegovy Prices So High?
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...
Senators press Novo Nordisk CEO on why Ozempic and Wegovy cost less abroad
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...
Novo Nordisk CEO grilled by Congress over Ozempic, Wegovy prices in US
For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...
Hitting the Pharmaceutical Jackpot With Novo’s Ozempic and Wegovy
Hi, it’s Bob in New York. I’ve been writing about drug costs for years, and Ozempic and Wegovy turn out to be in a unique ...
STAT3d
Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices
WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo ...
Vermont Business Magazine3d
Sanders leads HELP Committee hearing with Novo Nordisk CEO on Ozempic and Wegovy prices
Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to ...
$50 Billion in Sales Make Ozempic and Wegovy Prices Tougher to Justify
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
Sen. Bernie Sanders grills maker of Ozempic
On Capitol Hill lawmakers grilled the CEO of the company that makes popular weight loss drugs Ozempic and Wegovy.